Clinical Trials
2 trialsNCT06889493 2026-04-28
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
University of Miami
Phase 1 Recruiting
NCT05262556 2025-08-07
NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas
Case Comprehensive Cancer Center
Phase 1 Active not recruiting